Korttidsvækst hos børn med atopisk dermatitis behandlet med tacrolimus og hydrokortison-17-butyrat

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-004052-39-DK

Enrollment

Registered

2004-10-28

Start date

2005-01-05

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopisk dermatitis

Interventions

Trade Name: Locoid 0.1% Product Name: hydrokortisonbutyrat 1 mg/g Product Code: 5995 Pharmaceutical Form: Ointment Trade Name: Protopic 0.1% Product Name: Tacrolimus 0.1% Product Code: EU/1/02/201/00

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: To assess skin prick test data, bone collagen turnover and an inflammation parameter in urine. Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Pubertetsudvikling : Tanner stadie II - V. Avendelse af enhver form for antiinflammatorisk behandling af atopisk dermatitis en uge inden visit 1 i periode 1. Samtidig asthma bronchiale, og allergisk rhinoconjunktivitis, der kræver behandling med glukokortikoider Endokrinologiske sygdomme – herunder vækstforstyrrelser – eller andre kroniske sygdomme. Større operative indgreb 4 uger inden og under undersøgelsen. Højfebril sygdom (t>39.5) af mere end 3 dages varighed.

Design outcomes

Primary

Measure	Time frame
Main Objective: To assess short term growth in children with atopic dermatitis during treatment with tacrolimus 0.1% and hydrocortionebutyrate.;Secondary Objective: ;Primary end point(s): Mean lower leg grotwh rates	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026